ORL
Nikola Vučević
Ball Ranks' AI model projects Nikola Vučević as the No. 117 player in 2026-27 9-category fantasy basketball: 12.7 points, 6.9 rebounds, 2.6 assists, 0.5 steals, 0.5 blocks, 1.2 three-pointers per game on 50.3% from the field, 80.4% from the line, and 1.1 turnovers, in 25.0 minutes a night across 63 projected games.
Joined Orlando, giving the Magic the stretch center they lacked next to Paolo Banchero and Franz Wagner. Wendell Carter Jr.'s minutes are the ones at risk.NBA.com 2026 offseason deals
Value
2.41
GP
63
MPG
25
PTS
12.7
Ranking Trend
Lower rank is better. Full ranking history will expand after more ranking seasons are computed.
Stat Trend
Track role, durability, and category growth by season.
Within-Season Trend
Season History
Stored historical box-score aggregates for draft analysis.
| Season | Age | Team | GP | GS | MPG | Rank | Value | PTS | REB | AST | STL | BLK | 3PM | FG% | FGA | FT% | FTA | TO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26-27 Projection | 36 | ORL | 63 | 0 | 25 | #117 | 2.41 | 12.7 | 6.9 | 2.6 | 0.5 | 0.5 | 1.2 | 50.3% | 10.6 | 80.4% | 1.3 | 1.1 |
| 25-26 | 35 | BOS | 64 | 0 | 28.4 | #58 | 4.10 | 15.1 | 8.4 | 3.3 | 0.6 | 0.6 | 1.6 | 49.3% | 12.5 | 82.8% | 1.5 | 1.3 |
| 24-25 | 34 | CHI | 73 | 0 | 31.2 | #19 | 7.04 | 18.5 | 10.1 | 3.5 | 0.8 | 0.7 | 1.8 | 53.0% | 14.2 | 80.5% | 2 | 1.6 |
| 23-24 | 33 | CHI | 76 | 0 | 34.3 | #49 | 5.18 | 18 | 10.5 | 3.3 | 0.7 | 0.8 | 1.2 | 48.4% | 15.9 | 82.2% | 1.7 | 1.6 |
| 22-23 | 32 | CHI | 82 | 0 | 33.5 | #28 | 6.51 | 17.6 | 11 | 3.2 | 0.7 | 0.7 | 1.5 | 52.0% | 14 | 83.5% | 1.9 | 1.7 |
| 21-22 | 31 | CHI | 73 | 0 | 33.1 | #31 | 6.63 | 17.6 | 11 | 3.2 | 1 | 1 | 1.4 | 47.3% | 15.8 | 76.0% | 1.7 | 1.9 |
| 20-21 | 30 | CHI | 70 | 0 | 33.5 | #12 | 8.82 | 23.4 | 11.7 | 3.8 | 0.9 | 0.7 | 2.5 | 47.7% | 19.9 | 84.0% | 2.2 | 1.8 |
| 19-20 | 29 | ORL | 62 | 0 | 32.2 | #18 | 7.47 | 19.6 | 10.9 | 3.6 | 0.9 | 0.8 | 1.6 | 47.7% | 16.7 | 78.4% | 2.7 | 1.4 |
| 18-19 | 28 | ORL | 80 | 0 | 31.4 | #13 | 9.64 | 20.8 | 12 | 3.8 | 1 | 1.1 | 1.1 | 51.8% | 16.9 | 78.9% | 2.8 | 2 |
| 17-18 | 27 | ORL | 57 | 0 | 29.5 | #25 | 6.69 | 16.5 | 9.2 | 3.4 | 1 | 1.1 | 1.1 | 47.5% | 14.7 | 81.9% | 1.6 | 1.9 |
| 16-17 | 26 | ORL | 75 | 0 | 28.8 | #52 | 4.21 | 14.6 | 10.4 | 2.8 | 1 | 1 | 0.3 | 46.8% | 13.7 | 66.9% | 2.1 | 1.6 |
| 15-16 | 25 | ORL | 65 | 0 | 31.3 | #27 | 5.82 | 18.2 | 8.9 | 2.8 | 0.8 | 1.1 | 0 | 51.0% | 16.1 | 75.3% | 2.3 | 1.9 |
| 14-15 | 24 | ORL | 74 | 0 | 34.2 | #28 | 6.03 | 19.3 | 10.9 | 2 | 0.7 | 0.7 | 0 | 52.3% | 16.3 | 75.2% | 2.9 | 2 |
| 13-14 | 23 | ORL | 57 | 0 | 31.8 | #41 | 4.71 | 14.2 | 11 | 1.8 | 1.1 | 0.8 | 0 | 50.7% | 12.2 | 76.6% | 2.4 | 2 |
| 12-13 | 22 | ORL | 77 | 0 | 33.2 | #35 | 4.83 | 13.1 | 11.9 | 1.9 | 0.8 | 1 | 0 | 51.9% | 11.5 | 68.3% | 1.6 | 1.8 |
| 11-12 | 21 | PHI | 51 | 0 | 15.9 | #248 | -1.85 | 5.5 | 4.8 | 0.6 | 0.4 | 0.7 | 0.1 | 45.0% | 5.7 | 52.9% | 0.7 | 0.6 |